Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
NEXUS Study for the Treatment of de Novo Native Coronary Artery Lesions
This study has been completed.
Sponsored by: Cordis Corporation
Information provided by: Cordis Corporation
ClinicalTrials.gov Identifier: NCT00231283
  Purpose

The objective of this study is to evaluate the effectiveness and safety of the CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-Wire (OTW) Stent Delivery System (SDS) in patients with de novo native coronary artery lesions.


Condition Intervention Phase
Coronary Artery Disease
Device: CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS)
Phase III

MedlinePlus related topics: Coronary Artery Disease Heart Attack
Drug Information available for: Sirolimus
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Official Title: A Multicenter, Non-Randomized Study of the CYPHER NxT Sirolimus-Eluting Coronary Stent on BX SONIC OVER-THE-WIRE (OTW) Stent Delivery System(SDS)for the Treatment of de Novo Native Coronary Artery Lesions

Further study details as provided by Cordis Corporation:

Primary Outcome Measures:
  • Final residual diameter stenosis < 50% by Quantatative Coronary Angiography (QCA) using any percutaneous method, without the occurrence of death, Myocardial Infarction (MI), or repeat revascularization of the target lesion

Secondary Outcome Measures:
  • Composite of MACE defined as death, Myocardial Infarction (Q-wave and Non Q-wave), emergent Coronary Artery Bypass Graft (CABG) or Target Lesion Revascularization (TLR) at discharge and 30 days post-procedure. [ Time Frame: Discharge and 30 days post-procedure ]

Estimated Enrollment: 100
Study Start Date: April 2004
Study Completion Date: July 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or non-pregnant female patients 18 years of age
  2. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II) OR patients with documented silent ischemia;
  3. Treatment of a single de novo target lesion in a major native coronary artery;
  4. Target lesion is 2.5 mm and 3.5 mm in diameter (visual estimate);
  5. Target lesion is 30mm in length (visual estimate);
  6. Target lesion stenosis is > 50% and < 100% (visual estimate);

Exclusion Criteria:

  • 1. Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK > 2 times normal within the preceding 24 hours and the CK and CK-MB enzymes remain above normal at the time of treatment;

    2. Has unstable angina classified as Braunwald III B or C, or is having a peri-infarction angina;

    3. Significant (> 50%) stenoses proximal or distal to the target lesion that might require revascularization or impede runoff;

    4. Documented Left ventricular ejection fraction 25%;

    5. Totally occluded vessel (TIMI 0 level);

    6. Impaired renal function (creatinine > 3.0 mg/dl) at the time of treatment;

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00231283

Locations
United States, Texas
Texas Heart Institute
Houston, Texas, United States, 77030
Sponsors and Collaborators
Cordis Corporation
Investigators
Principal Investigator: Emerson Perin, MD Texas Heart Institute
  More Information

Study ID Numbers: P04-6324
Study First Received: September 30, 2005
Last Updated: May 2, 2007
ClinicalTrials.gov Identifier: NCT00231283  
Health Authority: United States: Food and Drug Administration

Study placed in the following topic categories:
Sirolimus
Arterial Occlusive Diseases
Coronary Disease
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Arteriosclerosis
Ischemia
Coronary Artery Disease

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 14, 2009